Off-label corneal cross-linking can be effective for correct patients

NEW YORK — Corneal cross-linking can slow or stop progression of keratoconus, but choosing the correct patients and deciding when to go off-label can help physicians improve outcomes.
Cross-linking may improve uncorrected and best corrected visual acuity and can lock in disease at its current level, which benefits milder cases more than severe cases. The FDA has approved corneal cross-linking for patients who are 14 years of age and older, who have progressive keratoconus or ectasia after refractive surgery, who are not pregnant and who have corneas that are 400 (Read more...)

Full Story →